| Today’s Big NewsOct 4, 2023 |
| By Kevin Dunleavy More than 30 companies and biopharma associations have introduced the Partnership for the US Life Science Ecosystem (PULSE) to increase awareness of the value of M&A. After successfully defending itself against the FTC lawsuit, Amgen is among the drugmakers who have signed on. AbbVie, Gilead, Merck and Novartis also are in the fold. |
|
|
|
By Annalee Armstrong Moderna’s combination COVID and flu shot demonstrated strong immunogenicity in a phase 1/2 trial and will speed on to phase 3 before the end of the year. |
By Conor Hale The medtech giant reported that it has found posts on various platforms looking to sell stolen medical hardware illegally, including its McGrath MAC video laryngoscopes. |
By Zoey Becker The generics and biosimilar maker debuted on the SIX Swiss Exchange at 24 Swiss francs ($26.16) for a total valuation of about $11.2 billion. Analysts had previously published ranges of $11 billion to $26 billion for the company, according to Reuters. |
|
Thursday, October 12, 2023 | 11am ET / 8am PT A fundamental research question continues to resonate today: How can we proactively develop countermeasures against future viral outbreaks? In this webinar, leaders in industry and academia discuss their experiences using innovative tools to study and develop therapeutics against influenza, SARS-CoV-2, dengue viruses, and more. Register now.
|
|
By Helen Floersh Fractyl Health’s GLP-1-based pancreatic gene therapy outperformed semaglutide injections for weight loss—at least in mice. |
By Fraiser Kansteiner After debuting its branded Humira biosim Cyltezo in July, Boehringer has launched an unbranded copycat of the inflammatory disease drug, simply called adalimumab-adbm injection, which will be sold at an 81% discount to Humira. By comparison, BI's Cyltezo carries a 5% discount to the brand. |
By Andrea Park "When I think about the future of CGM, I think it’s only going to continue to grow in its access and use around the globe and in broad populations," Dexcom COO Jake Leach said in an interview with Fierce Medtech. |
By Fraiser Kansteiner Colombian authorities say they plan to issue a compulsory license for ViiV Healthcare's dolutegravir, which goes by the name Tivicay on its own or as Dovato when combined with other therapeutics. The idea behind the compulsory license is to allow the Colombian government to purchase cheaper generic versions. |
By Kevin Dunleavy A New Jersey appeals court has vanquished a $223 million jury award to four plaintiffs who claimed asbestos in Johnson & Johnson's iconic baby powder caused their cancer. The Superior Court ruled that a lower court should not have allowed jurors to hear the testimony of three scientific experts. |
By Annalee Armstrong Andrew Miller, Ph.D., co-founder of Karuna, one-time CEO and now chief operating officer, detailed the long journey to get KarXT developed, from raiding Eli Lilly’s storeroom all the way to the FDA for schizophrenia, in an interview with Fierce Biotech. |
By Andrea Park Finnish tech maker GlucoModicum is hoping a partnership with Phillips-Medisize will bring good luck to the development of its Talisman noninvasive continuous glucose monitor. |
Fierce podcastsDon’t miss an episode |
| | Violence in healthcare workplaces is a growing concern, with clinicians and other workers facing alarming rates of violence on the job. In this week’s episode of “Podnosis,” Fierce Healthcare’s Anastassia Gliadkovskaya sits down with Andrea Mazzoccoli, Ph.D., the former chief nurse and quality officer for Bon Secours Mercy Health, to delve into the urgent need for comprehensive workplace violence strategies. |
|
|---|
|
|
|
Thursday, October 12, 2023 | 2pm ET / 11am PT In this webinar, we take a deep dive into different strategies for unifying enterprise-wide lab data. You'll learn how to drive better access, collaboration, and AI-driven insight. Don't miss out, register today.
|
|
| WebinarEmbark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
| eBookLearn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
| WhitepaperEconomic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
| WhitepaperFrom Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperLearn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| WhitepaperLearn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
| WhitepaperFrom trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| WhitepaperBy 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| |
|
